Somatostatin receptors as tools for diagnosis and therapy: Molecular aspects

被引：26

作者：

Guillermet-Guibert, J ^{[1
]}

Lahlou, H ^{[1
]}

Pyronnet, S ^{[1
]}

Bousquet, C ^{[1
]}

Susini, C ^{[1
]}

机构：

[1] INSERM, IFR31, Inst Louis Bugnard, U531, F-31432 Toulouse, France

来源：

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY | 2005年 / 19卷 / 04期

关键词：

somatostatin; receptors; signal transduction; endocrine tumour;

D O I：

10.1016/j.bpg.2005.03.007

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Somatostatin is a neuropeptide that acts as an endogenous inhibitor of various cellular functions including endocrine and exocrine secretions and the proliferation of normal and tumour cells. Its action is mediated by a family of G-protein-coupled receptors (sst1-sst5) that are widely distributed in normal and tumour cells. Gastroenteropancreatic endocrine tumours express multiple somatostatin receptors, sst2 being clearly predominant. These receptors represent the molecular basis for the clinical use of somatostatin analogues in the treatment of endocrine tumours and their in vivo localisation. This review covers current knowledge in somatostatin receptor biology and signalling.

引用

页码：535 / 551

页数：17

共 99 条

[1] Inhibition of endothelial proliferation by the somatostatin analogue SOM230 [J].

Adams, RL ;

Adams, IP ;

Lindow, SW ;

Atkin, SL .

CLINICAL ENDOCRINOLOGY, 2004, 61 (04) :431-436

[2] Novel long-acting somatostatin analog with endocrine selectivity: Potent suppression of growth hormone but not of insulin [J].

Afargan, M ;

Janson, ET ;

Gelerman, G ;

Rosenfeld, R ;

Ziv, O ;

Karpov, O ;

Wolf, A ;

Bracha, M ;

Shohat, D ;

Liapakis, G ;

Gilon, C ;

Hoffman, A ;

Stephensky, D ;

Oberg, K .

ENDOCRINOLOGY, 2001, 142 (01) :477-486

[3] Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis [J].

Albini, A ;

Florio, T ;

Giunciuglio, D ;

Masiello, L ;

Carlone, S ;

Corsaro, A ;

Thellung, S ;

Cai, T ;

Noonan, DM ;

Schettini, G .

FASEB JOURNAL, 1999, 13 (06) :647-655

[4] High-intensity p38 kinase activity is critical for p21cip1 induction and the antiproliferative function of Gi protein-coupled receptors [J].

Alderton, F ;

Humphrey, PPA ;

Sellers, LA .

MOLECULAR PHARMACOLOGY, 2001, 59 (05) :1119-1128

[5] Somatostatin receptor subtype-dependent regulation of nitric oxide release: Involvement of different intracellular pathways [J].

Arena, S ;

Pattarozzi, A ;

Corsaro, A ;

Schettini, G ;

Florio, T .

MOLECULAR ENDOCRINOLOGY, 2005, 19 (01) :255-267

[6] Treatment of neuroendocrine GEP tumours with somatostatin analogues - A review [J].

Arnold, R ;

Simon, B ;

Wied, M .

DIGESTION, 2000, 62 :84-91

[7]

BITO H, 1994, J BIOL CHEM, V269, P12722

[8] SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile [J].

Bruns, C ;

Lewis, I ;

Briner, U ;

Meno-Tetang, G ;

Weckbecker, G .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (05) :707-716

[9] Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs [J].

Buchsbaum, DJ .

SEMINARS IN NUCLEAR MEDICINE, 2004, 34 (01) :32-46

[10] Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients [J].

Cascinu, S ;

Del Ferro, E ;

Ligi, M ;

Staccioli, MP ;

Giordani, P ;

Catalano, V ;

Agostinelli, R ;

Muretto, P ;

Catalano, G .

CANCER INVESTIGATION, 2001, 19 (01) :8-12

← 1 2 3 4 5 6 7 8 9 10 →